Detalhe da pesquisa
1.
Characterization and Management of Adverse Reactions in Patients With Advanced Endometrial Cancer Receiving Lenvatinib Plus Pembrolizumab.
Oncologist
; 29(1): 25-35, 2024 Jan 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37523661
2.
Characterization and Management of Adverse Reactions in Patients with Advanced Endometrial Carcinoma Treated with Lenvatinib Plus Pembrolizumab.
Oncologist
; 26(9): e1599-e1608, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34190370